source
- BioNTech's anti-CTLA-4 drug shows survival advantage in advanced squamous lung cancer at WCLCBioNTech, together with partner OncoC4, presented new overall survival data at the World Conference on Lung Cancer in South Korea, joining other companies such as Summit Therapeutics, GSK and Roche…
- Scholar Rock receives FDA approval for apitegromab (Isembyld) to treat spinal muscular atrophyScholar Rock announced FDA approval for its injectable drug apitegromab, marketed as Isembyld, for treating spinal muscular atrophy, a rare muscle-wasting condition. The approval follows earlier s…